Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma

BACKGROUND: The treatment algorithm for metastatic non-small cell lung cancers (NSCLCs) has been evolving rapidly due to the development of new therapeutic agents. Although guidelines are provided by National Comprehensive Cancer Network (NCCN) for treatment options according to biomarker testing re...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shuyu D., Martial, Annia, Schrock, Alexa B., Liu, Jane J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674807/
https://www.ncbi.nlm.nih.gov/pubmed/29142786
http://dx.doi.org/10.1186/s40164-017-0089-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674807/
https://www.ncbi.nlm.nih.gov/pubmed/29142786
http://dx.doi.org/10.1186/s40164-017-0089-y

Ejemplares similares